Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100866 | 1.00 | TDP1 (0.58) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL9766176 | 1.00 | TDP1 (0.58) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL27275320 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL11015972 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL9099692 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL1132359 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL9642504 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL10579475 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL7804219 | 0.92 | TDP1 (0.59) | TDP1CTDSP1MAPK1MAPTPOLB | |
| SCHEMBL9699338 | 0.91 | TDP1 (0.58) | TDP1CTDSP1MAPK1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9677112-B2 | β-lactamase substrates and methods of their use for the diagnosis of tuberculosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-06-18 | — | — | US | disclosed |
| US-20100261897-A1 | Improved Process For the Preparation of Cephalosporin Antibiotic Intermediate | ORCHID CHEMICALS & PHARMACEUTICALS LTD, (IN) | 2010-10-14 | — | — | US | disclosed |
| US-5064649-A | CEPHALOSPORIN DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-11-12 | — | — | US | disclosed |
| EP-0359536-A2 | Cephalosporin compounds, process for their preparation and pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1990-03-21 | — | — | EP | disclosed |
| US-4668781-A | Ceph-3-one compounds and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1987-05-26 | — | — | US | disclosed |
| US-4591642-A | Cephem and cepham derivatives | CIBA-GEIGY CORPORATION (US) | 1986-05-27 | — | — | US | disclosed |
| US-4477658-A | Process for the preparation of cepham and cephem compounds | CIBA-GEIGY CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
| US-4405778-A | Process for preparing cephalosporin ethers | CIBA-GEIGY CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
| US-4389524-A | Cepham compounds | CIBA-GEIGY CORPORATION (US) | 1983-06-21 | — | — | US | disclosed |
| US-4073902-A | ANTIMICROBIAL COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
| US-3989695-A | 7β-Amino-cepham-3-ol-4-carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | PGLS, ENGASE, BPHL | TDP1 2256/4885CTDSP1 1636/4885MAPK1 4733/4885 |
| US-20100261897-A1 | Improved Process For the Preparation of Cephalosporin Antibiotic Intermediate | TFPI, TFPI2, DHCR7 | TDP1 2809/4885CTDSP1 104/4885MAPK1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.